NWRN — Newron Pharmaceuticals SpA Share Price
Last trade - 00:00- CH₣174.16m
- CH₣182.76m
- €19.13m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 5.82 | ||
| Price to Sales | 9.83 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -24.56% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 5.76 | 6.09 | 9.06 | 51.39 | 19.13 | 11.36 | 21.57 | 29.47% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Newron Pharmaceuticals SpA is an Italy-based company operating in the medical research sector. It is a biopharmaceutical company focused on the research, development, and commercialization of therapies for disorders of the central and peripheral nervous system (CNS). The Company specializes in neurological and psychiatric diseases, including schizophrenia and Parkinson’s disease. Its activities include drug discovery, clinical development, regulatory approval processes, and strategic licensing and commercialization partnerships with pharmaceutical companies worldwide. The Company has built a pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization, such as evenamide, safinamide and ralfinamide. Newron Pharmaceuticals SpA operates at global level.
Directors
- Ulrich Kostlin CHM
- Stefan Weber CEO
- Roberto Galli VFN
- Dennis Dionne VPR (70)
- Marco Caremi VBD
- Ravi Anand OTH
- Luca Benatti NED (60)
- Donald De Bethizy NED
- Robert Holland NED (63)
- Patrick Langlois NID (75)
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- April 17th, 2002
- Public Since
- December 12th, 2006
- No. of Employees
- 27
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 21,238,867
- Address
- via Antonio Meucci 3, BRESSO, 20091
- Web
- https://www.newron.com/
- Phone
- +39 026103461
- Auditors
- Ernst & Young SpA
Latest News for NWRN
Upcoming Events for NWRN
Similar to NWRN
Addex Therapeutics
SIX Swiss Exchange
BACHEM HOLDING AG
SIX Swiss Exchange
Basilea Pharmaceutica AG, Allschwil
SIX Swiss Exchange
BioVersys AG
SIX Swiss Exchange
EvoNext Holdings SA
SIX Swiss Exchange
FAQ
As of Today at 04:19 UTC, shares in Newron Pharmaceuticals SpA are trading at CH₣8.20. This share price information is delayed by 15 minutes.
Shares in Newron Pharmaceuticals SpA last closed at CH₣8.20 and the price had moved by -41.76% over the past 365 days. In terms of relative price strength the Newron Pharmaceuticals SpA share price has underperformed the FTSE Global All Cap Index by -48.98% over the past year.
The overall consensus recommendation for Newron Pharmaceuticals SpA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNewron Pharmaceuticals SpA does not currently pay a dividend.
Newron Pharmaceuticals SpA does not currently pay a dividend.
Newron Pharmaceuticals SpA does not currently pay a dividend.
To buy shares in Newron Pharmaceuticals SpA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣8.20, shares in Newron Pharmaceuticals SpA had a market capitalisation of CH₣174.16m.
Here are the trading details for Newron Pharmaceuticals SpA:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: NWRN
Based on an overall assessment of its quality, value and momentum Newron Pharmaceuticals SpA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Newron Pharmaceuticals SpA is CH₣33.43. That is 307.66% above the last closing price of CH₣8.20.
Analysts covering Newron Pharmaceuticals SpA currently have a consensus Earnings Per Share (EPS) forecast of -€1.49 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Newron Pharmaceuticals SpA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -52.02%.
As of the last closing price of CH₣8.20, shares in Newron Pharmaceuticals SpA were trading -44.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Newron Pharmaceuticals SpA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CH₣8.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Newron Pharmaceuticals SpA's management team is headed by:
- Ulrich Kostlin - CHM
- Stefan Weber - CEO
- Roberto Galli - VFN
- Dennis Dionne - VPR
- Marco Caremi - VBD
- Ravi Anand - OTH
- Luca Benatti - NED
- Donald De Bethizy - NED
- Robert Holland - NED
- Patrick Langlois - NID